PD-1/PD-L1 inhibitors, antibody-based therapies derived from immune checkpoint therapy and clinically approved for various types of cancers, can alleviate T-cell exhaustion and enhance the immune response towards cancer cells (47, 48). This evidence concerns the gene CD274 and cancer.